Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-03-14
2006-03-14
Davis, Zinna Northington (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07012146
ABSTRACT:
The present invention relates to ion channel modulating agents. More particularly, the present invention relates to a particular class of chemical compounds that has proven useful as modulators of SK Ca, IK Ca and BK Ca channels. In further aspects, the present invention relates to the use of these SK/IK/BK channel modulating agents for the manufacture of medicaments, for methods of therapy, and pharmaceutical compositions comprising the SK/IK/BK channel modulating agents. The SK/IK/BK channel modulating agents of the invention are useful for the treatment or alleviation of diseases and conditions associated with the SK/IK/BK channels.
REFERENCES:
patent: 3268540 (1966-08-01), Mohrbacher
patent: 6204277 (2001-03-01), Shinkai et al.
patent: 228192 (1986-01-01), None
patent: 9806720 (1998-02-01), None
Umemoto et al., “Power and Structure—Variable Fluorinating Agents. The N-Fluropyridinium Salt System”, J. Am. Chem. Soc. 1990, 112, 8563-8575.
Sammes et al., Synthetic Applications of N—N Linked Heterocyclies. Part 16. Reactions between Carbanions Derived from arbon Acid with pKa 7-14 and N-(2,6-dimethyl-4-oxopyridin-1-yl)pyridinium Tetrafluoroborate: Synthesis of 4-substituted pyridines, an.
Gargus, et al., “Unraveling Monogenic Channelopathies and Their Implications for Complex Polygenic Disease”, Am. J. Hum. Genet., 72:785-803, 2003.
Merlo et al., “Modifier genes in cystic fibrosis lung disease”, Journal of Laboratory and Clinical Medicine (2003), 141 (4), 237-241.
CA 128:204878 , “Preparation of pyrazinobenzothiazine derivatives and analogs fro the treatement of inflammation and autoimmune diseases”, Kaneko et al. cont. Observatin of Pyridine Ring-opening Reactions, p. 2835-2839.
Laohachai et. al., “The role of bacterial and non-bacterial toxins in the induction of changes in membrane transport: implications for diarrhea”, pp. 687-707.
Smerz et. al., “Nickel-Catalyzed Hydroxylation of 1,3-Dicarbonyl Compounds by Dimethyldioxirane”, Tetrahedron, vol. 52, No. 16, 5799-5804.
Miyoshi et al, Journal of Biological Chemistry, vol. 273, No. 28, pp. 17368-17374, 1998.
Andrako et al., J. Pharm. Sci., vol. 50, pp. 337-340 (1961).
Zymalkowski, Arch. Pharm., vol. 291, pp. 436-442 (1958).
Porter et al., Int. J. Peptide Protein Res. vol. 30, pp. 13-21 (1987).
Kawabata et al., Liebigs Ann. Chem., (1990) pp. 181-183.
Aldrich Catalog Handbook of Fine Chemicals, 1996-1997, pp. 510-525, 264-266, 268, 277, 278, 324, 385, 518, 563, 580, 597, 602, 622, 627, 997, 1010, 1064, 1458, and 1480.
Beyer Jurgen
Christophersen Palle
Jensen Bo Skaaning
Strobaek Dorte
Teuber Lene
Davis Zinna Northington
Poseidon Pharmaceuticals A/S
LandOfFree
Ion channel modulating agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ion channel modulating agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ion channel modulating agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3525508